dalteparin has been researched along with Ovarian Neoplasms in 13 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The main HGF pharmacokinetic parameters were evaluated following acute and chronic LMWH treatment." | 2.77 | Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications. ( Di Renzo, MF; Ferrero, A; Fuso, L; Luchin, A; Marchese, C; Martino, C; Passera, R; Surbone, A; Zola, P, 2012) |
| " A dose-response effect was not identified." | 2.77 | Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. ( Elit, LM; Hoskins, P; Julian, DH; Julian, JA; Lee, AY; Levine, MN; Liaw, PC; Parpia, S; Swystun, LL, 2012) |
| "A documented relationship between ovarian cancer and thrombosis does exist." | 1.46 | The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1. ( Chakroun, T; Elalamy, I; Gerotziafas, GT; Larsen, AK; Mbemba, E; Sassi, M; Van Dreden, P, 2017) |
| " Here we show that a therapeutic dosage of LMWH tinzaparin reverses cisplatin resistance of A2780cis human ovarian cancer cells to the level of sensitive cells." | 1.42 | Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells. ( Bendas, G; Pfankuchen, DB; Royer, HD; Schlesinger, M; Stölting, DP, 2015) |
| "Dalteparin 5000 U/day was used in both groups." | 1.40 | The value of extended preoperative thromboprophylaxis with dalteparin in patients with ovarian cancer qualified to surgical treatment. ( Dzieciuchowicz, L; Krasińska, B; Krasiński, Z; Pawlaczyk, K; Staniszewski, R; Szpurek, D; Urbanek, T; Wójcicka, K, 2014) |
| "To compare the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing gynecological operations without low molecular weight heparin (LMWH) prophylaxis and those receiving such prophylaxis." | 1.31 | Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of low molecular weight heparin. Gynecological ward retrospective analysis. ( Cyrkowicz, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Nagy, Z | 1 |
| Turcsik, V | 1 |
| Blaskó, G | 1 |
| Surbone, A | 1 |
| Fuso, L | 1 |
| Passera, R | 1 |
| Ferrero, A | 1 |
| Marchese, C | 1 |
| Martino, C | 1 |
| Luchin, A | 1 |
| Di Renzo, MF | 1 |
| Zola, P | 1 |
| Cyrkowicz, A | 1 |
| Yu, R | 1 |
| Nansubuga, F | 1 |
| Yang, J | 1 |
| Ding, W | 1 |
| Li, K | 1 |
| Weng, D | 1 |
| Wu, P | 1 |
| Chen, G | 1 |
| Ma, D | 1 |
| Wei, J | 1 |
| Patel, S | 1 |
| Sanborn, D | 1 |
| Issa, M | 1 |
| Sassi, M | 1 |
| Chakroun, T | 1 |
| Mbemba, E | 1 |
| Van Dreden, P | 1 |
| Elalamy, I | 1 |
| Larsen, AK | 1 |
| Gerotziafas, GT | 1 |
| Jones, JW | 1 |
| Uppal, S | 1 |
| Hernandez, E | 1 |
| Dutta, M | 1 |
| Dandolu, V | 1 |
| Rose, S | 1 |
| Hartenbach, E | 1 |
| Cook, C | 1 |
| Callaway, M | 1 |
| Krasiński, Z | 1 |
| Szpurek, D | 1 |
| Staniszewski, R | 1 |
| Dzieciuchowicz, L | 1 |
| Pawlaczyk, K | 1 |
| Krasińska, B | 1 |
| Wójcicka, K | 1 |
| Urbanek, T | 1 |
| Elit, LM | 1 |
| Lee, AY | 1 |
| Parpia, S | 1 |
| Swystun, LL | 1 |
| Liaw, PC | 1 |
| Hoskins, P | 1 |
| Julian, DH | 1 |
| Julian, JA | 1 |
| Levine, MN | 1 |
| Mueller, T | 1 |
| Pfankuchen, DB | 2 |
| Wantoch von Rekowski, K | 1 |
| Schlesinger, M | 2 |
| Reipsch, F | 1 |
| Bendas, G | 2 |
| Stölting, DP | 1 |
| Royer, HD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studio Pilota Farmacocinetico-clinico Sulla Somministrazione di Eparina a Basso Peso Molecolare e Dosaggio Sierico di HGF Nelle Pazienti Operate Affette da Patologie Ginecologiche[NCT01523652] | 29 participants (Actual) | Observational | 2007-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for dalteparin and Ovarian Neoplasms
| Article | Year |
|---|---|
The effect of LMWH (Nadroparin) on tumor progression.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; | 2009 |
Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Dose-Response Relationsh | 2012 |
Efficiency and safety evaluation of prophylaxes for venous thrombosis after gynecological surgery.
Topics: Anticoagulants; Arginine; Endometrial Neoplasms; Female; Gynecologic Surgical Procedures; Heparin, L | 2020 |
Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compoun | 2012 |
9 other studies available for dalteparin and Ovarian Neoplasms
| Article | Year |
|---|---|
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of low molecular weight heparin. Gynecological ward retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Electrocardiography; Female; Gynecologic Surgical Procedures; Hepari | 2002 |
57-Year-Old Woman With Weakness and Word-Finding Difficulties.
Topics: Adenocarcinoma, Clear Cell; Antibodies, Antiphospholipid; Aspirin; Biomarkers, Tumor; Cerebral Infar | 2021 |
The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.
Topics: Cell Line, Tumor; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa Inhibitors; Female; Fibrin | 2017 |
Venous thromboembolism: appropriate risk assessment and treatment can save lives.
Topics: Anticoagulants; Enoxaparin; Fatal Outcome; Female; Humans; Obesity; Ovarian Neoplasms; Pneumonia; Ri | 2010 |
Prolonged postoperative venous thrombo-embolism prophylaxis is cost-effective in advanced ovarian cancer patients.
Topics: Adult; Aged; Cost-Benefit Analysis; Enoxaparin; Female; Humans; Markov Chains; Middle Aged; Ovarian | 2012 |
Low molecular weight heparin and the risk of haemorrhage following percutaneous biopsy, despite a normal standard clotting screen.
Topics: Aged; Biopsy, Needle; Carcinoma, Endometrioid; Enoxaparin; Female; Hemorrhage; Humans; Iliac Vein; I | 2001 |
The value of extended preoperative thromboprophylaxis with dalteparin in patients with ovarian cancer qualified to surgical treatment.
Topics: Adult; Anticoagulants; Biomarkers; Dalteparin; Drug Administration Schedule; Female; Fibrin Fibrinog | 2014 |
The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergi | 2017 |
Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; | 2015 |